EGFR and lung cancer: At the time of initiation of FIELT in 2006, advanced lung cancer was treated indiscriminately with platinum-based chemotherapy and no data were available on the prospective first-line use of any EGFR TKI in phenotypically or genotypically selected NSCLC, while only retrospective data were available for gefitinib [14].